Form 4: MapLight Therapeutics Director Receives Stock Grant

Martin Babler, a Director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026.

Summary

• Director Martin Babler received a grant of 7,864 restricted stock units (RSUs) on June 23, 2026.
• These RSUs are part of the Issuer's 2025 Equity Incentive Plan and vest in three equal annual installments starting June 23, 2027.
• Babler also received a stock option to purchase 29,804 shares of voting common stock at an exercise price of $28.64.
• This stock option also vests in three equal annual installments beginning on June 23, 2027.
• Both the RSUs and stock options were granted under the company's non-employee director compensation policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard compensation for a director and does not contain new financial performance data or strategic shifts.

Positives

• Grant of equity awards (RSUs and stock options) to a director, indicating continued investment and alignment with the company's performance.
• The grants are structured with a vesting schedule, incentivizing long-term commitment from the director.
• The exercise price for the stock option is set at $28.64, which may reflect the current market value or a premium.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• Vesting of RSUs and stock options is contingent upon the Reporting Person's Continuous Service to the Issuer, meaning departure from the company before vesting dates will result in forfeiture of unvested awards.
• The value of the stock options is subject to market fluctuations and the company's stock performance.

Future Outlook

The vesting schedule for the RSUs and stock options indicates a forward-looking commitment from the director, tied to continued service over the next three years.

Industry Context

StockSavvy.ai notes that grants of equity awards to directors are a common practice in the biotechnology and pharmaceutical sectors, aligning executive and director interests with shareholder value creation through long-term incentives.

Stakeholder Impact

• Shareholders: The grants align director incentives with long-term shareholder value, but do not immediately impact share count or value.
• Employees: The filing pertains to director compensation and does not directly impact general employee compensation or roles.
• Management: The grants reinforce the compensation structure for non-employee directors.

Next Steps

• Vesting of RSUs and stock options will occur in three equal annual installments beginning on June 23, 2027, subject to continued service.
• The stock option is exercisable until its expiration date of June 22, 2036.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Equity Incentive Plan, Director Compensation, MapLight Therapeutics, MPLT